Education
About Us
Working with TipRanks
Follow Us
Prelude Therapeutics, Inc. (PRLD)
:PRLD
Total Valuation
Prelude Therapeutics has a market cap or net worth of $50.98M. The enterprise value is ―.
Market Cap$50.98M
Enterprise Value―
Share Statistics
Prelude Therapeutics has 43,610,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,610,220
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Prelude Therapeutics’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -91.57%.
Return on Equity (ROE)-0.97
Return on Assets (ROA)-0.72
Return on Invested Capital (ROIC)-91.57%
Return on Capital Employed (ROCE)-0.93
Revenue Per Employee53.44K
Profits Per Employee-970.79K
Employee Count131
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Prelude Therapeutics is -0.76. Prelude Therapeutics’s PEG ratio is -0.08.
PE Ratio-0.76
PS Ratio0.00
PB Ratio0.43
Price to Fair Value0.73
Price to FCF-0.40
Price to Operating Cash Flow-0.55
PEG Ratio-0.08
Income Statement
In the last 12 months, Prelude Therapeutics had revenue of 7.00M and earned -127.17M in profits. Earnings per share was -1.68.
Revenue7.00M
Gross Profit7.00M
Operating Income-139.71M
Pretax Income-127.17M
Net Income-127.17M
EBITDA-139.71M
Earnings Per Share (EPS)-1.68
Cash Flow
In the last 12 months, operating cash flow was -102.89M and capital expenditures -764.00K, giving a free cash flow of -103.65M billion.
Operating Cash Flow-102.89M
Free Cash Flow-103.65M
Free Cash Flow per Share-2.38
Dividends & Yields
Prelude Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change-78.04%
50-Day Moving Average0.78
200-Day Moving Average1.83
Relative Strength Index (RSI)56.99
Average Volume (3m)138.07K
Important Dates
Prelude Therapeutics upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Prelude Therapeutics as a current ratio of 5.30, with Debt / Equity ratio of 13.71%
Current Ratio5.30
Quick Ratio5.30
Debt to Market Cap0.19
Net Debt to EBITDA-0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Prelude Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Prelude Therapeutics EV to EBITDA ratio is -0.73, with an EV/FCF ratio of -0.98.
EV to Sales14.55
EV to EBITDA-0.73
EV to Free Cash Flow-0.98
EV to Operating Cash Flow-0.99
Balance Sheet
Prelude Therapeutics has $133.61M in cash and marketable securities with $18.02M in debt, giving a net cash position of -$115.59M billion.
Cash & Marketable Securities$133.61M
Total Debt$18.02M
Net Cash-$115.59M
Net Cash Per Share-$2.65
Tangible Book Value Per Share$1.73
Margins
Gross margin is 87.46%, with operating margin of -1995.91%, and net profit margin of -1816.76%.
Gross Margin87.46%
Operating Margin-1995.91%
Pretax Margin-1816.76%
Net Profit Margin-1816.76%
EBITDA Margin-1995.91%
EBIT Margin-1995.91%
Analyst Forecast
The average price target for Prelude Therapeutics is $3.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.33
Price Target Upside270.00% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast16.38%